Alta Life Sciences

Founded 2016
Founders Guy P. Nohra

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$23M
Portfolio companies 9
Rounds per year 2.20
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Therapeutics
  • Health Diagnostics
Summary

Alta Life Sciences is the famous VC, which was founded in 2016. The main office of represented VC is situated in the Barcelona. The company was established in Europe in Spain.

Among the various public portfolio startups of the fund, we may underline SANIFIT, Mediktor, Bionure The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Spain. We can highlight the next thriving fund investment areas, such as Wellness, Health Care. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

The high activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually. Speaking about the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.

This organization was formed by Guy P. Nohra.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Alta Life Sciences, startups are often financed by Ministerio de Economia y Competitividad, Healthequity, Caixa Capital Risc. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Naos, Lundbeckfonden Ventures. In the next rounds fund is usually obtained by Horizon 2020.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Binx Health

Biotechnology
Health Care
Health Diagnostics
Medical Device
Mobile
$104M27 May 2021 Boston, Massachusetts, United States

INBRAIN Neuroelectronics

Biotechnology
Consumer Electronics
Medical Device
$16M26 Mar 2021 Barcelona, Catalonia, Spain

Inbiomotion

Biotechnology
Genetics
Health Diagnostics
Therapeutics
21 Jan 2021 Spain, Catalonia

Peptomyc

Biotechnology
Health Care
Wellness
$13M15 Dec 2020 Barcelona, Catalonia, Spain

DeepUll

Biotechnology
Diagnostic Equipment
Life Science
Therapeutic Devices
$4M07 Jul 2020 Spain, Catalonia

Ona Therapeutics

Biotechnology
Health Care
Life Science
$35M16 Jun 2020 Spain, Catalonia

INBRAIN Neuroelectronics

Biotechnology
Consumer Electronics
Medical Device
$1M11 Jun 2020 Spain, Catalonia

Accure Therapeutics

Biotechnology
Therapeutics
$8M26 May 2020 Barcelona, Catalonia, Spain

SANIFIT

Biotechnology
Hospital
Medical
$65M26 Jun 2019 Palma De Mallorca, Islas Baleares, Spain
News
INBRAIN Neuroelectronics Secures $17 Million in Series A Funding for First AI-Powered Graphene-Brain Interface

– INBRAIN Neuroelectronics S.L. announced $16.8m in Series A funding for its disruptive system for treating epilepsy and Parkinson’s disease.
– The investment was co-led by Asabys Partners and Alta Life Sciences and joined by Vsquared Ventures and TruVenturo GmbH.
– The funding will be used to advance INBRAIN’s first-in-human clinical program, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices.
– INBRAIN’s technology harnesses the power of graphene, a two-dimensional material first isolated in 2004 made of a lattice of carbon atoms only one atom thick.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Alta Life Sciences?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: